CN103209687A - 包含地拉罗司的药物组合物 - Google Patents

包含地拉罗司的药物组合物 Download PDF

Info

Publication number
CN103209687A
CN103209687A CN201180047621XA CN201180047621A CN103209687A CN 103209687 A CN103209687 A CN 103209687A CN 201180047621X A CN201180047621X A CN 201180047621XA CN 201180047621 A CN201180047621 A CN 201180047621A CN 103209687 A CN103209687 A CN 103209687A
Authority
CN
China
Prior art keywords
pharmaceutical composition
described pharmaceutical
deferasirox
inhibitor
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180047621XA
Other languages
English (en)
Chinese (zh)
Inventor
G·马尔霍特拉
S·M·普兰德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103209687(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of CN103209687A publication Critical patent/CN103209687A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180047621XA 2010-10-01 2011-09-30 包含地拉罗司的药物组合物 Pending CN103209687A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2750/MUM/2010 2010-10-01
IN2750MU2010 2010-10-01
PCT/GB2011/001428 WO2012042224A2 (en) 2010-10-01 2011-09-30 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CN103209687A true CN103209687A (zh) 2013-07-17

Family

ID=44802316

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180047621XA Pending CN103209687A (zh) 2010-10-01 2011-09-30 包含地拉罗司的药物组合物

Country Status (18)

Country Link
US (3) US20140147503A1 (enExample)
EP (1) EP2621471A2 (enExample)
JP (1) JP2013538845A (enExample)
KR (1) KR20140011300A (enExample)
CN (1) CN103209687A (enExample)
AP (1) AP3578A (enExample)
AU (1) AU2011309872B2 (enExample)
BR (1) BR112013007276A2 (enExample)
CA (1) CA2812505A1 (enExample)
EC (1) ECSP13012534A (enExample)
IL (1) IL225457A (enExample)
MX (1) MX2013003522A (enExample)
MY (1) MY165826A (enExample)
NZ (1) NZ608380A (enExample)
PE (2) PE20140166A1 (enExample)
RU (1) RU2589842C2 (enExample)
WO (1) WO2012042224A2 (enExample)
ZA (1) ZA201302092B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105828805A (zh) * 2013-08-07 2016-08-03 学校法人近畿大学 纳米粒子和纳米粒子组合物以及用于生产纳米粒子和纳米粒子组合物的方法
CN107693516A (zh) * 2016-08-08 2018-02-16 上海宣泰医药科技有限公司 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
CN107847490A (zh) * 2015-06-17 2018-03-27 分散技术有限责任公司 改进的地拉罗司制剂及制备其的方法
CN110891549A (zh) * 2017-04-07 2020-03-17 玛亚实验室公司 改善治疗剂的溶解度和生物利用度的方法
CN115154428A (zh) * 2022-09-06 2022-10-11 上海奥科达生物医药科技有限公司 一种地拉罗司药物组合物及其制备方法
CN115400088A (zh) * 2022-09-06 2022-11-29 上海奥科达生物医药科技有限公司 一种地拉罗司药物组合物及其制备方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064834A2 (en) 2010-11-09 2012-05-18 Cornell University Methods for organ regeneration
US20150246027A1 (en) 2012-11-12 2015-09-03 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferiprone
WO2014136079A1 (en) 2013-03-08 2014-09-12 Novartis Ag Oral formulations of deferasirox
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
JP2016518398A (ja) * 2013-05-10 2016-06-23 シプラ・リミテッド 低用量医薬組成物
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015114314A1 (en) * 2014-01-28 2015-08-06 Cipla Limited Pharmaceutical composition comprising abiraterone
IN2014MU00916A (enExample) * 2014-03-20 2015-09-25 Cipla Ltd
KR20160088965A (ko) * 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CA3029543C (en) * 2016-07-05 2021-11-23 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
US12419884B2 (en) 2018-08-06 2025-09-23 Brigham Young University Compositions and methods for treating iron overload
PE20230382A1 (es) 2020-05-18 2023-03-06 Orexo Ab Nueva composicion farmaceutica para administracion de farmacos
IL313016A (en) 2021-11-25 2024-07-01 Orexo Ab A pharmaceutical preparation that includes adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
WO2010035282A1 (en) * 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1708343A1 (ru) * 1989-09-22 1992-01-30 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ получени твердых лекарственных форм
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
DE60137362D1 (de) * 2000-11-20 2009-02-26 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
US6509380B1 (en) * 2001-12-14 2003-01-21 Marshall University Research Corporation Method of treating iron overload with acetaminophen
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US7531351B2 (en) * 2004-06-14 2009-05-12 Probiogen Ag Liquid-gas-phase exposure reactor for cell culturing
JP2009512652A (ja) 2005-10-19 2009-03-26 ノバルティス アクチエンゲゼルシャフト 安息香酸誘導体含有分散錠
US20090016359A1 (en) * 2007-07-11 2009-01-15 Samsung Electronics Co., Ltd. System and method for processing high definition video data to be transmitted over a wireless medium
US20090142395A1 (en) * 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
WO2009130604A2 (en) * 2008-04-21 2009-10-29 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
WO2010035282A1 (en) * 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105828805A (zh) * 2013-08-07 2016-08-03 学校法人近畿大学 纳米粒子和纳米粒子组合物以及用于生产纳米粒子和纳米粒子组合物的方法
CN105828805B (zh) * 2013-08-07 2020-06-23 学校法人近畿大学 纳米粒子和纳米粒子组合物以及用于生产纳米粒子和纳米粒子组合物的方法
CN107847490A (zh) * 2015-06-17 2018-03-27 分散技术有限责任公司 改进的地拉罗司制剂及制备其的方法
CN107693516A (zh) * 2016-08-08 2018-02-16 上海宣泰医药科技有限公司 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
CN107693516B (zh) * 2016-08-08 2020-06-26 上海宣泰医药科技有限公司 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
CN110891549A (zh) * 2017-04-07 2020-03-17 玛亚实验室公司 改善治疗剂的溶解度和生物利用度的方法
US12268786B2 (en) 2017-04-07 2025-04-08 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
CN115154428A (zh) * 2022-09-06 2022-10-11 上海奥科达生物医药科技有限公司 一种地拉罗司药物组合物及其制备方法
CN115400088A (zh) * 2022-09-06 2022-11-29 上海奥科达生物医药科技有限公司 一种地拉罗司药物组合物及其制备方法
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN115400088B (zh) * 2022-09-06 2023-07-07 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Also Published As

Publication number Publication date
US20140147503A1 (en) 2014-05-29
NZ608380A (en) 2014-10-31
WO2012042224A8 (en) 2013-04-11
EP2621471A2 (en) 2013-08-07
ECSP13012534A (es) 2013-10-31
US20180311216A1 (en) 2018-11-01
IL225457A (en) 2017-04-30
AP3578A (en) 2016-02-08
RU2589842C2 (ru) 2016-07-10
WO2012042224A3 (en) 2012-08-09
KR20140011300A (ko) 2014-01-28
MY165826A (en) 2018-05-17
AU2011309872A1 (en) 2013-04-11
WO2012042224A2 (en) 2012-04-05
CA2812505A1 (en) 2012-04-05
JP2013538845A (ja) 2013-10-17
MX2013003522A (es) 2013-05-22
PE20140166A1 (es) 2014-02-17
AP2013006785A0 (en) 2013-04-30
AU2011309872B2 (en) 2014-09-04
US20160324831A1 (en) 2016-11-10
IL225457A0 (en) 2013-06-27
BR112013007276A2 (pt) 2016-06-14
RU2013120275A (ru) 2014-11-20
ZA201302092B (en) 2013-11-27
PE20170468A1 (es) 2017-04-26

Similar Documents

Publication Publication Date Title
CN103209687A (zh) 包含地拉罗司的药物组合物
AU2011244783B2 (en) Pharmaceutical compositions
JP5484910B2 (ja) レバプラザン含有の固体分散体及びその製造方法
AU2003226021B2 (en) Drug microparticles
JP6192244B2 (ja) 改良されたバイオアベイラビリティを有する薬学的組成物
CN102438594A (zh) 吲哚美辛的新剂型
CN101801347A (zh) 包含二氢吡啶类钙通道拮抗剂的改进的药物组合物及其制备方法
WO2015071668A1 (en) Pharmaceutical compositions
CN104955482A (zh) 包含地拉罗司和去铁酮的固定剂量的药物组合物
JP2016518398A (ja) 低用量医薬組成物
JP2013518860A (ja) Ｎ−（２−クロロ−６−メチルフェニル）−２−［［６−［４−（２−ヒドロキシエチル）−１−ピペラジニル］−２−メチル−４−ピリミジニル］アミノ］−５−チアゾールカルボサキミドを含む医薬組成物
JP2012516346A (ja) ピリドピリミジノンの経口用固体製剤
JP6666352B2 (ja) デュタステリド含有固体分散体及びこれを含む組成物
EP2311435A1 (en) Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
OA16350A (en) Pharmaceutical composition comprising deferasirox.
OA16372A (en) Reclaimer machine.
MX2012012084A (es) Composicion farmaceutica.
WO2011148253A2 (en) Solid dosage forms of antipsychotics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130717